Biomerica

Biomerica EBITDA per Employee

The EBITDA per Employee of Biomerica (BMRA) as of Nov 2, 2026 is -98,518.52 USD. In the previous year, EBITDA per Employee was -95,129.63 USD — a change of 3.56% (lower).

EBITDA per Employee

-98,518.52USD

YoY

3.56%

Last updated:

EBITDA per Employee of Biomerica is 2026 -98,518.52 USD. EBITDA per Employee of Biomerica was 2025 -95,129.63 USD. It decreases by 3.56% lower compared to the previous year.

The Biomerica EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2019
-44,681.30 USD
Jan 1, 2020
-44,497.19 USD
Jan 1, 2021
-138,883.20 USD
Jan 1, 2022
-83,962.30 USD
Jan 1, 2023
-133,759.26 USD
Jan 1, 2024
-117,907.41 USD
Jan 1, 2025
-95,129.63 USD
Jan 1, 2026
-98,518.52 USD
The Biomerica EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-98,518.52USD+3.56%
-95,129.63USD-19.32%
-117,907.41USD-11.85%
-133,759.26USD+59.31%
-83,962.30USD-39.54%
-138,883.20USD+212.12%
-44,497.19USD-0.41%
-44,681.30USD+62.83%
-27,439.91USD+55.22%
-17,678.39USD+15.44%
-15,313.93USD+23.32%
-12,418.43USD+50.16%
-8,270.26USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

EBITDA per Employee of Biomerica is -98,518.52 USD in 2026.

EBITDA per Employee of Biomerica changed from -95,129.63 USD to -98,518.52 USD, representing a 3.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Biomerica since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Biomerica historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Biomerica

All Key Metrics — Biomerica